|
1
|
Woo JS, Alberti MO and Tirado CA:
Childhood B-acute lymphoblastic leukemia: A genetic update. Exp
Hematol Oncol. 3:162014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tasian SK, Loh ML and Hunger SP: Childhood
acute lymphoblastic leukemia: Integrating genomics into therapy.
Cancer. 121:3577–3590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harvey RC, Mullighan CG, Wang X, Dobbin
KK, Davidson GS, Bedrick EJ, Chen IM, Atlas SR, Kang H, Ar K, et
al: Identification of novel cluster groups in pediatric high-risk
B-precursor acute lymphoblastic leukemia with gene expression
profiling: Correlation with genome-wide DNA copy number
alterations, clinical characteristics and outcome. Blood.
116:4874–4884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vrooman LM and Silverman LB: Treatment of
childhood acute lymphoblastic leukemia: Prognostic factors and
clinical advances. Curr Hematol Malig Rep. 11:385–394. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jaime-Perez JC, Pinzon-Uresti MA,
Jimenez-Castillo RA, Colunga-Pedraza JE, Gonzalez-Llano O and
Gomez-Almaguer D: Relapse of childhood acute lymphoblastic leukemia
and outcomes at a reference center in Latin America: Organomegaly
at diagnosis is a significant clinical predictor. Hematology.
23:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhojwani D and Pui CH: Relapsed childhood
acute lymphoblastic leukaemia. Lancet Oncol. 14:e205–e217. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhojwani D, Yang JJ and Pui CH: Biology of
childhood acute lymphoblastic leukemia. Pediatr Clin North Am.
62:47–60. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Inaba H, Greaves M and Mullighan CG: Acute
lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bykov VJN, Eriksson SE, Bianchi J and
Wiman KG: Targeting mutant p53 for efficient cancer therapy. Nat
Rev Cancer. 18:89–102. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aubrey BJ, Strasser A and Kelly GL:
Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb
Perspect Med. 6(pii): a0260622016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhukova N, Ramaswamy V, Remke M, Pfaff E,
Shih DJ, Martin DC, Castelo-Branco P, Baskin B, Ray PN, Bouffet E,
et al: Subgroup-specific prognostic implications of TP53 mutation
in medulloblastoma. J Clin Oncol. 31:2927–2935. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu P, Liu X, Ouyang J and Chen B: TP53
mutation predicts the poor prognosis of non-Hodgkin lymphomas:
Evidence from a meta-analysis. PLoS One. 12:e01748092017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Poulain S, Roumier C, Bertrand E,
Renneville A, Caillault-Venet A, Doye E, Geffroy S, Sebda S,
Nibourel O, Nudel M, et al: TP53 mutation and its prognostic
significance in Waldenstrom's Macroglobulinemia. Clin Cancer Res.
23:6325–6335. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Petitjean A, Achatz MI, Borresen-Dale AL,
Hainaut P and Olivier M: TP53 mutations in human cancers:
Functional selection and impact on cancer prognosis and outcomes.
Oncogene. 26:2157–2165. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zenz T, Eichhorst B, Busch R, Denzel T,
Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G,
et al: TP53 mutation and survival in chronic lymphocytic leukemia.
J Clin Oncol. 28:4473–4479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
ang Y, Xu X, Song H, Yang S, Shi S and Wei
J: Long-term outcome of childhood acute lymphoblastic leukemia
treated in China. Pediatr Blood Cancer. 51:380–386. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stengel A, Schnittger S, Weissmann S,
Kuznia S, Kern W, Kohlmann A, Haferlach T and Haferlach C: TP53
mutations occur in 15.7% of ALL and are associated with
MYC-rearrangement, low hypodiploidy and a poor prognosis. Blood.
124:251–258. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rabinovich GA, Gabrilovich D and Sotomayor
EM: Immunosuppressive strategies that are mediated by tumor cells.
Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Welch JS, Petti AA, Miller CA, Fronick CC,
O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon
B, et al: TP53 and Decitabine in acute myeloid leukemia and
myelodysplastic syndromes. N Engl J Med. 375:2023–2036. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stengel A, Kern W, Haferlach T,
Meggendorfer M, Fasan A and Haferlach C: The impact of TP53
mutations and TP53 deletions on survival varies between AML, ALL,
MDS and CLL: An analysis of 3307 cases. Leukemia. 31:705–711. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Prokocimer M, Molchadsky A and Rotter V:
Dysfunctional diversity of p53 proteins in adult acute myeloid
leukemia: Projections on diagnostic workup and therapy. Blood.
130:699–712. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Montalban-Bravo G, Takahashi K and
Garcia-Manero G: Decitabine in TP53-mutated AML. N Engl J Med.
376:796–797. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bolouri H, Farrar JE, Triche T Jr, Ries
RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, et al:
The molecular landscape of pediatric acute myeloid leukemia reveals
recurrent structural alterations and age-specific mutational
interactions. Nat Med. 24:103–112. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qiu X, You Y, Huang J, Wang X, Zhu H and
Wang Z: LAMP3 and TP53 overexpression predicts poor outcome in
laryngeal squamous cell carcinoma. Int J Clin Exp Pathol.
8:5519–5527. 2015.PubMed/NCBI
|
|
26
|
Elliott MA, Litzow MR, Letendre LL, Wolf
RC, Hanson CA, Tefferi A and Tallman MS: Early peripheral blood
blast clearance during induction chemotherapy for acute myeloid
leukemia predicts superior relapse-free survival. Blood.
110:4172–4174. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zeidler L, Zimmermann M, Möricke A,
Meissner B, Bartels D, Tschan C, Schrauder A, Cario G, Goudeva L,
Jäger S, et al: Low platelet counts after induction therapy for
childhood acute lymphoblastic leukemia are strongly associated with
poor early response to treatment as measured by minimal residual
disease and are prognostic for treatment outcome. Haematologica.
97:402–409. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Andrysik Z, Galbraith MD, Guarnieri AL,
Zaccara S, Sullivan KD, Pandey A, MacBeth M, Inga A and Espinosa
JM: Identification of a core TP53 transcriptional program with
highly distributed tumor suppressive activity. Genome Res.
27:1645–1657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muller-Thomas C, Rudelius M, Rondak IC,
Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M,
Peschel C, et al: Response to azacitidine is independent of p53
expression in higher-risk myelodysplastic syndromes and secondary
acute myeloid leukemia. Haematologica. 99:e179–e181. 2014.
View Article : Google Scholar : PubMed/NCBI
|
